Latikafusp represents a unique medical strategy for treating particular cancers, particularly those involving fusion anaplastic lymphoma kinase proteins. This drug functions as an blocker of shortened anaplastic lymphoma kinase proteins, demonstrating potential in preclinical investigations and initial clinical assessments. Its mode of effect offer